Effect of ABO Blood Group Incompatibility on the Outcome of Single-Unit Cord Blood Transplantation after Myeloablative Conditioning

• Published in: Biology of blood and marrow transplantation Vol. 20; no. 4; pp. 577 - 581
• Main Authors: Konuma, Takaaki, Kato, Seiko, Ooi, Jun, Oiwa-Monna, Maki, Ebihara, Yasuhiro, Mochizuki, Shinji, Yuji, Koichiro, Ohno, Nobuhiro, Kawamata, Toyotaka, Jo, Norihide, Yokoyama, Kazuaki, Uchimaru, Kaoru, Tojo, Arinobu, Takahashi, Satoshi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-04-2014
• Subjects: ABO Blood-Group System - immunology; ABO incompatibility; Adolescent; Adult; Blood Group Incompatibility - immunology; Cord Blood Stem Cell Transplantation - methods; Cord blood transplantation; Female; Graft Survival; Graft vs Host Disease - immunology; Graft vs Host Disease - mortality; Graft vs Host Disease - pathology; Graft-versus-host disease; Hematologic Neoplasms - immunology; Hematologic Neoplasms - mortality; Hematologic Neoplasms - pathology; Hematologic Neoplasms - therapy; Hematology, Oncology and Palliative Medicine; Humans; Male; Middle Aged; Myeloablative Agonists - therapeutic use; Myeloablative conditioning; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Graft-versus-host disease; Myeloablative conditioning; ABO incompatibility; Cord blood transplantation
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1016/j.bbmt.2013.12.563

Abstract ABO blood group incompatibility between donor and recipient has been associated with poor transplant outcomes in allogeneic hematopoietic stem cell transplantation. However, its effect on the outcome of cord blood transplantation (CBT) has yet to be clarified. We retrospectively analyzed 191 adult patients who received single-unit CBT after myeloablative conditioning for malignant disease in our institute. Major mismatch showed a significantly lower incidence of platelet engraftment compared with ABO match as a reference (hazard ratio, .57; P  = .01). Nevertheless, there was no increase in graft-versus-host disease, transplant-related mortality, and overall mortality after ABO-incompatible CBT. These data suggested that donor–recipient ABO incompatibility does not have a significant impact on outcome after myeloablative CBT for hematological malignancies.